GITR-induced IL-9 promoted tumor-specific CD8+ cytotoxic T lymphocyte (CTL) response by upregulating the expression of costimulatory and MHC II molecules and increasing the crosspresentation capacity of GITR ligand- (GITRL-) expressing DCs in a melanoma tumor model. This evidence concerns the gene IL9 and neoplasm.